SERMs (Tamoxifen, Toremifene and Fulvestrant), perform their action by binding to the oestrogen receptor [22]; in breast tissue, Tamoxifen acts as an ER antagonist, inhibiting the activity of oestrogens and, for this reason, it is commonly used as to treat breast cancer. The gene discussed is ESR1; the disease is breast cancer.